Sickle Cell Disease
810
132
185
409
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
173 trials with published results (21%)
Research Maturity
409 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.5%
85 terminated out of 810 trials
82.8%
-3.8% vs benchmark
11%
90 trials in Phase 3/4
42%
173 of 409 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 409 completed trials
Clinical Trials (810)
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.
Acupressure in Patients With Sickle Cell Disease
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
Integrative Medicine in Pain Management in Sickle Cell Disease
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
Blood Collection for Research Related to Certain Diseases Involving Blood Vessels
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
Blood Sampling for Research Related to Sickle Cell Disease
Cooperative Assessment of Late Effects for SCD Curative Therapies
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease